about
Evaluation of clonal origin of malignant mesotheliomaMinimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesotheliomaLatest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapiesCombined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700sFTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse modelPositive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesotheliomaHMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma.Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progressionBAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs.Evidence-based guidelines: Improving AGREEment on consistence evaluationHMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients.Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-α signaling.Investigating palygorskite's role in the development of mesothelioma in southern Nevada: Insights into fiber-induced carcinogenicityWide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma.Germline BAP1 mutations induce a Warburg effectBAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation.Preclinical development of HIvax: Human survivin highly immunogenic vaccinesImproving the Accuracy of Mesothelioma Diagnosis in China.Malignant Mesothelioma: Time to Translate?Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw.Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients.Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside.Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas.Progress in the Management of Malignant Pleural Mesothelioma in 2017.Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin.Concerns About Presence of a Wild-Type BAP1 Allele in Absence of Nuclear Protein Expression.A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline MutationsImatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenibSplicing molecular biology and novel therapies in diffuse malignant peritoneal mesotheliomaPDGFRα inhibition in soft-tissue sarcomas: Have we gotten it all wrong?New frontiers in the medical management of gastrointestinal stromal tumours.Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving NivolumabSecondary KIT mutations: the GIST of drug resistance and sensitivityUse of Cardioprotective Dexrazoxane Is Associated with Increased Myelotoxicity in Anthracycline-Treated Soft-Tissue Sarcoma PatientsUnexpected benefit from an 'old' metronomic chemotherapy regimen in advanced chordomaFamilial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis
P50
Q21146661-E177CFC6-C646-4F27-B994-8F67D65DD41AQ28389071-E11AC6D3-A4A7-4603-802D-A6E7CD05C8E0Q28395597-CA04DDC5-254D-4379-99CD-BC3857DAD7A2Q28396964-37905C8F-86A4-4D32-8029-123A3F86293BQ29248124-C5D5B1A2-9FDA-4652-9A6B-55FC9AE90936Q29248126-FAD240C4-0DA7-4420-800A-69B57F796B40Q33618428-01B9C2E4-6E6D-4A77-BE38-CBE2F9EA85D3Q34917972-DDDE5DE6-9D32-4DAE-8F75-B3AFA35543F1Q36347346-14B2A3C1-CA38-4705-9262-CCC5F3EE0511Q36384018-76A67665-933D-433E-BED3-3184A181687FQ36491364-B08332B2-9592-4AC4-8253-7691B6DCFDD0Q36901529-6F7AF73D-C89B-4354-9291-79963BE84F27Q37271498-B5FE4647-B0F3-464F-AD92-8F7D8712B3F7Q37335386-1AFF8FD9-B5AA-4AF8-AFB4-792F563302B0Q37760957-33E6645C-8846-4D9C-9655-0725C94DFAC9Q38429562-CF4175B0-E0D3-4B60-98A0-73B0673CD5A2Q38700344-76628216-A5D4-4BA0-AE8C-230192F54C5EQ38725838-218836BA-4F31-4458-A2C6-6554DFD563ECQ38867680-552BF653-079B-4603-ADC2-D64E5A09F944Q39051001-F11C1D1A-7F8B-4593-83D6-0CF4FEF7D3A7Q39366003-05FDA2FA-710E-437E-B6CA-D208A2F051FCQ42424855-DCBDF067-CE2B-4B95-9BC5-A1FC1FB00E76Q42480495-4EC589B0-449E-4F00-BAD9-1423A1676EACQ45743838-BB5F7887-E65F-446E-BEBC-7DC967288EA9Q47792575-4DB3D2A7-D5FA-4DA9-B7D4-76FCA5AEB33DQ52663125-B4604764-B54E-4162-84BF-43F260D17250Q52671546-8620FBBB-526B-40C9-9313-0DEF0EDC0ADDQ53281137-8DDC37ED-CE98-4B73-BD54-90B8552688A6Q58096223-8155B0C8-D4F2-476F-9F56-92882A1A1AB5Q58695210-68C50C31-012B-4EFE-A1D1-A300F62F2FABQ61806918-DF80AD2C-4733-4CD8-98CF-1382E1F0E1DAQ64261870-852E730C-DD9E-4030-B6A9-E85C3F29E8C1Q64948703-63D8A17D-5E49-42B3-8DC4-FA7414F60741Q89500693-D615DA9E-0E4A-4D06-95B1-B1BB08D8544EQ91816304-A40CC730-CE71-4128-B0E2-2184C2E50B4EQ92477891-CB7D0885-D936-467B-8D14-59AB6A856520Q92500228-50C90DDE-AB91-4340-BF7B-01D354CB8560Q92771652-EE2AF9B1-1229-4B00-BEF1-99210D6DEA5F
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Andrea Napolitano
@ast
Andrea Napolitano
@en
Andrea Napolitano
@es
Andrea Napolitano
@fr
Andrea Napolitano
@nl
Andrea Napolitano
@sl
type
label
Andrea Napolitano
@ast
Andrea Napolitano
@en
Andrea Napolitano
@es
Andrea Napolitano
@fr
Andrea Napolitano
@nl
Andrea Napolitano
@sl
prefLabel
Andrea Napolitano
@ast
Andrea Napolitano
@en
Andrea Napolitano
@es
Andrea Napolitano
@fr
Andrea Napolitano
@nl
Andrea Napolitano
@sl
P106
P1153
36876538300
P2038
Andrea_Napolitano
P21
P31
P496
0000-0002-7509-1555